

Table 1: Characteristics of participants in the newly-diagnosed T2D cohorts

	PNDS	VNDS	GDS
N	496	661	406
Clinical parameters			
Age, years	54 (45, 63)	60 (52, 66)	54 (47, 60)
Women, n (%)	162 (33)	221 (33)	148 (36)
BMI, kg/m ²	28.8 (25.7, 32.9)	29.4 (26.8, 32.9)	31.1 (27.3, 35.5)
Active smoking, n (%)	80 (17)	113 (18)	91 (22)
Immune cell profile			
Leukocyte, G/L	6.30 (5.20, 7.50)	6.20 (5.30, 7.30)	6.80 (5.90, 7.90)
Neutrophil, G/L	3.50 (2.60, 4.45)	3.86 (3.41, 4.47)	3.90 (3.15, 4.62)
Lymphocyte, G/L	2.12 (1.65, 2.52)	2.08 (1.72, 2.57)	2.24 (1.80, 2.66)
Monocyte, G/L	0.47 (0.38, 0.58)	0.47 (0.39, 0.59)	0.40 (0.28, 0.55)
Insulin secretion and insulin sensitivity			
HOMA2-B, %	65 (46, 91)	69 (41, 111)	89 (64, 121)
HOMA2-IR	1.71 (1.33, 2.38)	3.70 (2.40, 5.80)	2.5 (1.8, 3.3)
Metabolic and biochemical profiles			
HbA1c, %	6.9 (6.3, 8.0)	6.6 (6.2, 7.3)	6.3 (5.9, 6.9)
hs-CRP, mg/L	1.9 (0.9, 4.2)	2.2 (1.2, 4.2)	2.5 (1.2, 5.3)
Total cholesterol, g/L	1.83 (1.54, 2.12)	1.87 (1.61, 2.14)	1.98 (1.75, 2.26)
LDL-cholesterol, g/L	1.11 (0.88, 1.36)	1.29 (1.08, 1.54)	1.28 (1.05, 1.51)
HDL-cholesterol, g/L	0.43 (0.36, 0.50)	0.43 (0.37, 0.51)	0.45 (0.38, 0.53)
Triglycerides, g/L	1.10 (0.79, 1.63)	1.23 (0.90, 1.77)	1.28 (0.94, 1.94)
AST, UI/L	28 (23, 34)	20 (15, 25)	23 (19, 29)
ALT, UI/L	29 (21, 43)	27 (21, 37)	30 (21, 41)
eGFR, ml/min/1.73m ²	98 (85, 108)	-	88 (76, 97)
Medications usage			
Biguanide (%)	327 (66)	98 (15)	215 (53)
Sulfonylurea (%)	67 (14)	27 (4)	6 (1)
DDP4 inhibitors (%)	63 (13)	0 (0)	26 (6)
GLP1-RA (%)	52 (10)	0 (0)	1 (0)
SGLT2 inhibitors (%)	19 (4)	0 (0)	2 (0)
Insulin (%)	49 (10)	8 (1)	31 (8)

Continuous variables were reported as median (first quartile, third quartile) or mean (standard deviation) and categorical variables as frequencies (percentages).

Table 2: Characteristics of participants in the longitudinal T2D cohorts

	CODIA	SURDIAGENE	ANGIOSAFE
N	71,409	920	3,307
Clinical parameters			
Age, years	61 (47, 71)	64 (10)	61 (53, 68)
Women, n (%)	36,357 (51)	388 (42)	1,284 (39)
Diabetes duration, years	11.1 (3.1, 22.3)	13.6 (9.5)	11 (4, 18)
Active smoking, n (%)	12,567 (18)	99 (11)	403 (14)
ASCVD history, n (%)	-	169 (18)	543 (18)
BMI, kg/m ²	28.0 (24.5, 32.2)	31.4 (5.9)	28.4 (25.3, 32.2)
Immune cell profile			
Leukocyte, G/L	6.70 (5.50, 8.00)	6.70 (5.60, 7.90)	6.50 (5.40, 7.70)
Neutrophil, G/L	4.00 (2.00, 6.00)	4.00 (3.10, 4.90)	3.66 (2.84, 4.61)
Lymphocyte, G/L	1.90 (1.00, 2.80)	1.90 (1.50, 2.40)	1.99 (1.59, 2.44)
Monocyte, G/L	0.50 (0.30, 0.70)	0.50 (0.40, 0.60)	0.47 (0.39, 0.58)
Metabolic and biochemical profiles			
HbA1c, %	6.2 (5.0, 7.7)	7.8 (1.6)	7.6 (6.8, 8.7)
hs-CRP (mg/L)	3.0 (1.1, 5.2)	2.9 (1.3, 5.5)	1.9 (0.8, 3.9)
Lipids profile (mmol/L)			
HDL cholesterol	1.30 (1.00, 1.60)	0.47 (0.16)	0.44 (0.37, 0.53)
LDL cholesterol	2.50 (1.90, 3.20)	1.02 (0.35)	1.00 (0.78, 1.26)
Triglyceride	1.30 (0.90, 1.90)	1.36 (0.97, 2.04)	1.15 (0.82, 1.68)
eGFR, mL/min/1.73m ²	106.8 (95.7, 122.9)	76.7 (19.5)	92 (74, 102)

Continuous variables were reported as median (first quartile, third quartile) or mean (standard deviation) and categorical variables as frequencies (percentages).

Table 3: Characteristics of participants in the Hyper-preDIL Study and the ABOS Study

	Hyper-preDIL	ABOS
N	20	529
Clinical parameters		
Age, years	50 (14)	47 (8)
Women, n (%)	11 (55)	333 (63)
BMI, kg/m ²	37 (34, 42)	48 (9)
Immune cell profile		
Leukocyte, G/L	7.92 (1.43)	8.41 (2.30)
Neutrophil, G/L	4.79 (1.13)	5.54 (4.85)
Lymphocyte, G/L	2.24 (0.60)	2.50 (1.78)
Monocyte, G/L	0.55 (0.17)	0.62 (0.56)
Metabolic and biochemical profiles		
HbA1c, %	5.9 (5.7, 6.0)	7.57 (1.64)
hs-CRP, mg/L	3.6 (2.4, 6.0)	6.38 (3.40)
Total cholesterol, g/L	4.52 (1.13)	4.78 (1.06)
LDL-cholesterol, g/L	2.60 (0.95)	2.79 (0.88)
HDL-cholesterol, g/L	1.24 (0.29)	1.07 (0.26)
Triglycerides, g/L	1.71 (0.63)	-
eGFR, ml/min/1.73m ²	89 (18)	94 (30)

Continuous variables were reported as median (first quartile, third quartile) or mean (standard deviation) and categorical variables as frequencies (percentages).